Tag Archive for: CRS

Poolbeg Pharma plc – Notice of Allowance received for POLB 001 Cancer Immunotherapy-induced CRS patent in Israel

/in

Continued momentum in Poolbeg’s global intellectual property strategy 21 July 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it has received a Notice of Allowance for its POLB 001 cancer immunotherapy-induced Cytokine Release Syndrome (“CRS”) patent application from the Israeli Patent […]

Read more

Poolbeg Pharma Plc – Placing to raise £3.5 million, Executive Chair Cathal Friel subscribes for £250,000

/in

Poolbeg Pharma Plc (AIM: POLB), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, is pleased to announce that it has raised £3.5 million (before expenses) pursuant to a placing of 58,333,328 new ordinary shares of 0.02 pence each in the capital of the Company (“Placing Shares”) with certain existing institutional and other investors (“Placing”). […]

Read more

Poolbeg Pharma plc – First Patient Dosed in the POLB 001 TOPICAL Clinical Trial

/in

Interim data remains on track for summer 2026 and partnering discussions continue to advance with multiple companies Highlights ·    First patient dosed in the POLB 001 TOPICAL clinical trial ·    Second site, University College London Hospital, activated with patient recruitment underway ·    Additional clinical sites expected to open imminently, supporting continued patient recruitment 13 July 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or […]

Read more

Poolbeg Pharma plc – Decision to grant European Patent received for POLB 001 in cancer immunotherapy-induced CRS

/in

Major milestone will provide IP protection in key European markets, strengthening global patent portfolio 16 June 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it has received formal notification of the decision to grant for its POLB 001 cancer immunotherapy-induced […]

Read more

Poolbeg Pharma plc – Two posters with POLB 001 preclinical data presented at the European Hematology Association Congress

/in

Posters highlight POLB 001’s potential in CRS prevention and ability to enhance AML treatment in elderly patients, potentially expanding into a new indication  ·    First poster shows that POLB 001 decreased key CRS-associated cytokines and did not impair bispecific antibody-induced tumour cell death in a series of preclinical investigations ·    Second poster demonstrates the potential for POLB […]

Read more
© Optimum Strategic Communications.